Population-based outcomes of patients (pt) with early-stage HER2-positive breast cancer treated with adjuvant trastuzumab (T).

被引：0
|
作者：
Noonan, Krista
McCarthy, Joy S.
机构：
[1] BC Canc Agcy, Vancouver, BC, Canada
[2] Dr H Bliss Murphy Canc Ctr, St John, NF, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e11079
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines
    Genuino, Anne Julienne
    Chaikledkaew, Usa
    Guerrero, Anna Melissa
    Reungwetwattana, Thanyanan
    Thakkinstian, Ammarin
    BMC HEALTH SERVICES RESEARCH, 2019, 19 (01)
  • [22] Cost-Effectiveness Analysis of Adjuvant Neratinib Following Trastuzumab in Early-Stage HER2-Positive Breast Cancer
    Schwartz, Naomi R. M.
    Flanagan, Meghan R.
    Babigumira, Joseph B.
    Steuten, Lotte M.
    Roth, Joshua A.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2019, 25 (10): : 1133 - 1139
  • [23] Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines
    Anne Julienne Genuino
    Usa Chaikledkaew
    Anna Melissa Guerrero
    Thanyanan Reungwetwattana
    Ammarin Thakkinstian
    BMC Health Services Research, 19
  • [24] Deescalating Adjuvant Trastuzumab in HER2-Positive Early-Stage Breast Cancer: A Systemic Review and Meta-Analysis
    Goldvaser, Hadar
    Korzets, Yasmin
    Shepshelovich, Daniel
    Yerushalmi, Rinat
    Sarfaty, Michal
    Ribnikar, Domen
    Thavendiranathan, Paaladinesh
    Amir, Eitan
    JNCI CANCER SPECTRUM, 2019, 3 (02)
  • [25] Cost-Effectiveness Analysis of Adjuvant Neratinib Following Trastuzumab in Early-Stage HER2-Positive Breast Cancer
    Tran, Phuong T.
    Diaby, Vakaramoko
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2020, 26 (02): : 221 - 221
  • [26] Adjuvant trastuzumab regimen for HER2-positive early-stage breast cancer: a systematic review and meta-analysis
    Genuino, Anne Julienne
    Chaikledkaew, Usa
    The, Due Ong
    Reungwetwattana, Thanyanan
    Thakkinstian, Ammarin
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2019, 12 (08) : 815 - 824
  • [27] Management and Outcome of HER2-Positive Early Breast Cancer Treated With or Without Trastuzumab in the Adjuvant Trastuzumab Era
    Palmieri, Carlo
    Shah, Deep
    Krell, Jonathan
    Gojis, Ondrej
    Hogben, Katy
    Riddle, Pippa
    Ahmad, Riz
    Tat, Tri
    Fox, Kevin
    Porter, Andrew
    Mahmoud, Sarah
    Kirschke, Stephanie
    Shousha, Sami
    Gudi, Mihir
    Coombes, R. Charles
    Leonard, Robert
    Cleator, Susan
    CLINICAL BREAST CANCER, 2011, 11 (02) : 93 - 102
  • [28] Real-world clinical outcomes of patients with stage I HER2-positive breast cancer treated with adjuvant paclitaxel and trastuzumab
    Debien, Veronique
    Agostinetto, Elisa
    Sirico, Marianna
    Jacobs, Flavia
    Molinelli, Chiara
    Moreau, Michel
    Paesmans, Marianne
    De Giorgi, Ugo
    Santoro, Armando
    Taylor, Donatienne
    Duhoux, Francois P.
    Botticelli, Andrea
    Barchiesi, Giacomo
    Lambertini, Matteo
    de Azambuja, Evandro
    Piccart, Martine
    CANCER RESEARCH, 2023, 83 (05)
  • [29] Real-world clinical outcomes of patients with stage I HER2-positive breast cancer treated with adjuvant paclitaxel and trastuzumab
    Debien, Veronique
    Marta, Guilherme Nader
    Agostinetto, Elisa
    Sirico, Marianna
    Jacobs, Flavia
    Molinelli, Chiara
    Moreau, Michel
    Paesmans, Marianne
    De Giorgi, Ugo
    Santoro, Armando
    Taylor, Donatienne
    Duhoux, Francois P.
    Botticelli, Andrea
    Barchiesi, Giacomo
    Speranza, Iolanda
    Lambertini, Matteo
    Wildiers, Hans
    de Azambuja, Evandro
    Piccart, Martine
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2023, 190
  • [30] Neratinib in Early-Stage HER2-Positive Breast Cancer
    Cherian, Mathew A.
    Ma, Cynthia X.
    BREAST DISEASES, 2015, 26 (04): : 285 - 287
12345